Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitricardia
- Development stage
- Preclinical
- Lead developer
- Bryan Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nitricardia is a small molecule therapeutic being developed by Bryan Therapeutics, Inc. (BTI) for the treatment of ischemic heart disease, including coronary artery disease and angina. Formulated as an orally disintegrating tablet (ODT), Nitricardia is designed to modulate the endothelial nitric oxide synthase (NOS) pathway. By enhancing nitric oxide signaling, the drug aims to promote vasodilation and improve coronary blood flow, thereby alleviating symptoms of myocardial ischemia. The program is currently in the preclinical stage, with clinical development expected to begin in the near future.
- Brand names
- Nitricardia
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on Nitricardia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nitricardia.